Episode 23: Real-world study of intranasal ketamine for use in patients with refractory chronic migraine episode artwork

EPISODE · Jan 22, 2024 · 32 MIN

Episode 23: Real-world study of intranasal ketamine for use in patients with refractory chronic migraine

from RAPM Focus · host BMJ Group

RAPM Editor-in-Chief Brian Sites, MD, joins Hsiangkuo Yua, MD, PhD, and Aniket Natekar, MD, two coauthors of “Real-world study of intranasal ketamine for use in patients with refractory chronic migraine,” first published in May 2023. Dr. Hsiangkuo Yuan received his medical degree from National Yang-Ming University in Taipei, Taiwan, and a PhD in biomedical engineering at Duke University. He joined Jefferson Headache Center in 2014 as a research fellow, then completed a neurology residency and headache fellowship at Thomas Jefferson University. Dr. Yuan is currently an associate professor of neurology and the director of clinical research at the Jefferson Headache Center. He is also the vice chair of ASRA Headache SIG and an associate editor of RAPM. His research interests include real world analysis of novel migraine therapeutics and a fundamental understanding of CSF dynamics in patients with CSF high and low pressure headaches. Dr. Aniket Natekar pursued his medical education at the John A. Burns School of Medicine at the University of Hawaii in Honolulu. He attended Thomas Jefferson University Hospital in Philadelphia, where he completed his residency in general neurology, and then a fellowship in headache medicine at the Jefferson Headache Center. Dr. Natekar is currently a practicing neurologist with a subspecialty training in headache management. Migraine is a common and disabling headache disorder with huge societal implications in terms of human suffering and loss of productivity. The World Health Organization recognizes its importance by ranking it in seventh place among worldwide diseases causing disability. Refractory chronic migraine headache is a subset condition of migraines. As the name suggests, it is an extremely unfortunate situation with limited treatment options. *The purpose of this podcast is to educate and to inform. The content of this podcast does not constitute medical advice, and it is not intended to function as a substitute for a healthcare practitioner’s judgement, patient care, or treatment. The views expressed by contributors are those of the speakers. BMJ does not endorse any views or recommendations discussed or expressed on this podcast. Listeners should also be aware that professionals in the field may have different opinions. By listening to this podcast, listeners agree not to use its content as the basis for their own medical treatment or for the medical treatment of others. Podcast and music produced by Dan Langa. Find us on Twitter @RAPMOnline. #headache #headachedisorder #migraine #refractorychronicmigraine #respiratorycomplications #intranasalketamine #regionalanesthesia #chronicpain #anesthesia #pain #painmanagement #MedEd #medicine

Episode metadata supplied by the publisher feed · Published Jan 22, 2024

Embed this episode

Ready to play

Episode 23: Real-world study of intranasal ketamine for use in patients with refractory chronic migraine

0:00 32:07

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of RAPM Focus?

This episode is 32 minutes long.

When was this RAPM Focus episode published?

This episode was published on January 22, 2024.

Can I download this RAPM Focus episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!